Cann Group has clear focus on commercial activity and revenue growth
August 31, 2023 at 01:36 pm EDT
Share
(via NewsDirect)
Cann Group Ltd (ASX:CAN) chairman Julian Chick talks Proactive through the medicinal cannabis producer’s F23 highlights. The company enjoyed revenue from sales of $13.78 million - representing a 115% increase on FY22 - while total revenue for the year came in at $21.68 million. He says the improvement was driven by the domestic market, with strong sales momentum supported by new clients entering into supply agreements and several existing clients with repeat orders. Cann’s flagship Mildura facility has now been commercially harvesting for over a year, with the facility’s latest harvested crop area equating to an annualised production level of 8 tonnes – double the size of previous harvests.
Cann’s CEO, Peter Koetsier said of the results, “Cann Group has made considerable progress over the course of the 2023 financial year. Most notably, the completion of construction on the company’s flagship Mildura facility has now allowed Cann to truly pursue its goal of becoming Australia’s premier B2B medicinal cannabis supplier.
“This state-of-the-art facility represents a substantial investment and an asset that must be fully utilised to capitalise on its capabilities and production efficiencies. As we continue our growth towards Mildura’s 12.5-tonne, optimal capacity, we expect Cann to prove to be a globally competitive and profitable business.”
“The company is now focused on scaling production of its high-quality portfolio, as well as fully resourcing our sales and marketing in an effort to quickly build revenue.”
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Cann Group Limited is an Australia-based company that is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research, cultivation and good manufacturing practices (GMP) manufacturing facilities are located in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.